Progetti FP7 coordinati da "Medizinische hochschule hannover"
| # | ||||
|---|---|---|---|---|
| 1 | RSM BCA2 CHARACTERIZATION OF THE ANTIVIRAL ACTIVITY OF BCA2 | 0 | 161˙968.00 | 161˙968.00 |
| 2 | ASTHMA AND ORMDL3 Understanding of ORMDL3 biology will provide novel insight into the pathogenesis of asthma | 2009 | 174˙087.00 | 174˙087.00 |
| 3 | NEUROBID Neuroscience on Barriers in Development | 2010 | 4˙194˙375.00 | 2˙996˙324.00 |
| 4 | ADENOSINE The role of adenosine in placental development and function | 2010 | 75˙000.00 | 75˙000.00 |
| 5 | NEONATAL B CELLS Functional analysis of the neonatal B cell compartment | 2010 | 100˙000.00 | 100˙000.00 |
| 6 | STEM CELL IMAGING Molecular imaging of the myocardium to facilitate cardiac stem cell therapy | 2011 | 100˙000.00 | 100˙000.00 |
| 7 | ENSIG-MIRNA Endocannabinoid signaling in heart failure: functional relevance of microRNAs | 2011 | 75˙000.00 | 75˙000.00 |
| 8 | BIOHYBRID Biohybrid templates for peripheral nerve regeneration | 2011 | 7˙755˙600.00 | 5˙922˙000.00 |
| 9 | ESPOIR European clinical study for the application of regenerative heart valves | 2012 | 6˙645˙283.00 | 5˙200˙000.00 |
| 10 | NATURIMMUN Natural Killer Cell-Based Anti-Cancer Immunotherapies: Research training in molecular medicine and biotechnology business | 2012 | 3˙526˙286.00 | 3˙526˙286.00 |
| 11 | TECAS Towards Tissue Engineering Solutions for Cardiovascular Surgery | 2013 | 3˙340˙211.00 | 3˙340˙211.00 |
| 12 | LYMPHATICS-HOMING Lymph node homing of immune cells via afferent lymphatics – mechanisms and immune response | 2013 | 2˙491˙200.00 | 2˙491˙200.00 |
| 13 | INMA Immune and Neuromodulation Mediated by Alphaherpesviruses | 2014 | 100˙000.00 | 100˙000.00 |
Altri progetti
L'Ente medizinische hochschule hannover partecipato anche in questi progetti.
- DACOTA (2010, participant)
- NEO-CIRC (2011, participant)
- MULTISCALEHUMAN (2011, participant)
- OPEN (2011, participant)
- IMMUNOCAN (2012, participant)
- BETABAT (2011, participant)
- EU-MASCARA (2011, participant)
- BIOMARCARE (2011, participant)
- BAMI (2011, participant)
- EMTICS (2011, participant)
- INTREALL (2011, participant)
- TRANS-INT (2012, participant)
- NEUEAR (2012, participant)
- PROHEARING (2012, participant)
- LIVERFIBROSISIMAGING (2012, beneficiary)
- CELLEUROPE (2012, participant)
- TRACENTREAT (2012, participant)
- OPTIBIRTH (2012, participant)
- TS-EUROTRAIN (2012, participant)
- HEMIBIO (2011, participant)
- CHILD-EU (2012, participant)
- BIOMARGIN (2013, participant)
- PAEON (2013, participant)
- LYMPHATICS-HOMING (2013, hostInstitution)
- LYMPHATICS-HOMING (2013, hostInstitution)
- HOMAGE (2013, participant)
- AGORA (2013, participant)
- FIBRO-TARGETS (2013, participant)
- ASTERIX (2013, participant)
- ACTION (2013, participant)
- GLYCOPAR (2013, participant)
- EPITARGET (2013, participant)
- IIP (2014, beneficiary)
- RAREDISEASEPLATFORM (2008, participant)
- EURO-PADNET (2008, participant)
- EVA (2008, participant)
- ADAPT (2008, participant)
- TARCC (2008, participant)
- EFRAIM (2008, participant)
- SHLOW (2008, participant)
- MITOTARGET (2009, participant)
- PERSIST (2009, participant)
- BIOSCENT (2009, participant)
- ENCE-CF-LAM-LTX (2009, participant)
- CASPER (2009, participant)
- WOUND CONTRACTION (2009, beneficiary)
- NAIMIT (2009, participant)
- MONAD (2009, participant)
- SICA-HF (2009, participant)
- MOLD-ERA (2010, participant)
- ACADEMIC GMP (2010, participant)
- CELL-PID (2010, participant)
- INTERQUALITY (2010, participant)
- HEPACUTE (2010, participant)
- p-medicine (2011, participant)
- EUROGENTEST2 (2011, participant)
- CORLINE (2011, participant)
- OPTI-FOX (2010, participant)